Previous 10 | Next 10 |
SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics , Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human anti-thymocyte immunoglobulin (hIgG) for disease-modification of Type 1 Diabetes (T...
First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG) SAB-142 directly and specifically targets multiple immune cells involved in the destruction of insulin-producing pancreatic beta cells to potenti...
SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T...
2023-11-14 09:25:10 ET More on SAB Biotherapeutics SAB Biotherapeutics GAAP EPS of -$0.14 Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics Financial information for SAB Biotherapeutics For fur...
Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditions Participating investors include Sessa Capital, BVF Partners, RTW Investments, Marshall Wace, ATW, and the JDRF T1D Fund Funds are expected to su...
Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors Received approval by the Human Research Ethics Committee (HREC) to commence a First-in-Human Phase 1 clinical trial investigating SAB-142 in Australia Appoints Michael G...
SAB Biotherapeutics Inc. (SABS) is expected to report $-0.1 for Q3 2023
SIOUX FALLS, S.D., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics , Inc. (Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or prog...
2023-11-06 08:41:02 ET More on SAB Biotherapeutics SAB Biotherapeutics GAAP EPS of -$0.14 Financial information for SAB Biotherapeutics For further details see: SAB Biotherapeutics files to sell 412.7M units to noteholders
2023-10-24 08:00:12 ET More on SAB Biotherapeutics SAB Biotherapeutics GAAP EPS of -$0.14 Seeking Alpha’s Quant Rating on SAB Biotherapeutics Historical earnings data for SAB Biotherapeutics For further details see: SAB Biotherapeutics gets new fin...
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc. Company Name:
SABS Stock Symbol:
NASDAQ Market:
SAB Biotherapeutics Inc. Website:
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is one of today's top gainers. The company's shares have moved 0% on the day to $2.77. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advance...
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB...
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progre...